一品红：子公司创新药APH03621片获得临床试验注册申请受理

Core Viewpoint - The announcement indicates that the innovative drug APH03621, developed by the company's wholly-owned subsidiary, has received acceptance for clinical trial application from the National Medical Products Administration, marking a significant step in the drug's development for treating endometriosis [1] Group 1: Drug Development - APH03621 is a novel oral, non-peptide small molecule gonadotropin-releasing hormone receptor antagonist (GnRH-ant) [1] - The drug is specifically aimed at treating endometriosis, a condition that currently lacks approved oral GnRH small molecule antagonists in the domestic market [1]